Advances in Antiviral Therapy: Acydovir

Ellen Gould Chadwick*, Stanford T. Shulman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Abstract: Acyclovir [9‐(2‐hydroxyethoxymethyl)guanine] is a newly licensed acyclic nucleoside analog that is active in vitro and in vivo against herpes simplex virus (HSV) and varicella zoster virus (VZV). This agent is available in the United States in topical and intravenous forms, and the oral preparation is currently being evaluated in clinical trials. The precise therapeutic role for acyclovir in patients with herpesvirus infections is still evolving. This article reviews the current status of this exciting new antiviral agent.

Original languageEnglish (US)
Pages (from-to)64-70
Number of pages7
JournalPediatric dermatology
Issue number1
StatePublished - Jul 1984

ASJC Scopus subject areas

  • Dermatology
  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Advances in Antiviral Therapy: Acydovir'. Together they form a unique fingerprint.

Cite this